What is Genomic Expression?
Genomic Expression is at the forefront of RNA analysis, leveraging its proprietary OneRNA platform. This advanced technology empowers healthcare professionals and patients by enabling precise disease detection, continuous health monitoring, and the design of next-generation cures. The platform's capabilities extend to drug repurposing for personalized treatments and accelerating the development of novel RNA therapeutics, with a particular focus on advancing cancer care. By integrating AI and prioritizing scalability, Genomic Expression is strategically positioning itself as a leader in the rapidly evolving RNA diagnostics and therapeutics sector.
How much funding has Genomic Expression raised?
Genomic Expression has raised a total of $4.3M across 2 funding rounds:
Grant
$4.2M
Debt
$50K
Grant (2018): $4.2M, investors not publicly disclosed
Debt (2021): $50K led by PPP
Key Investors in Genomic Expression
PPP
Public-Private Partnership
What's next for Genomic Expression?
The recent substantial expansion capital infusion suggests Genomic Expression is entering a critical scaling phase, likely focused on further developing its OneRNA platform, expanding its market reach, and potentially initiating clinical trials or broader commercialization efforts. The company's enterprise-level funding context indicates a strategic push towards solidifying its market position and accelerating its pipeline of RNA-based diagnostics and therapeutics. Future growth will likely involve strategic partnerships and continued innovation in personalized medicine and oncology.
See full Genomic Expression company page
